Ropinirole in the treatment of Parkinson's disease: An update;Ropinirol en el tratamiento de la enfermedad de Parkinson: Actualización

Revista de Neurologia

Volumn 42, Issue 9, 2006, Pages 542-548

  Vivancos Matellano, Francisco ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Dyskinesias; Neuroprotector; Parkinson's disease; Ropinirole; Therapeutic window

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ANTIPARKINSON AGENT; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; PLACEBO;

CLINICAL TRIAL; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DYSKINESIA; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; SYMPTOM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; DRUG SCREENING; METABOLISM; PATHOPHYSIOLOGY;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PLACEBOS;

EID: 33750128441     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4209.2005737     Document Type: Review

References (52)

1. Martínez-Martín P. Datos históricos del tratamiento farmacológico de la enfermedad de Parkinson. In López-Muñoz F, Álamo-González C, eds. Historia de la neuropsicofarmacología. Madrid: Eurobook; 1998. p. 387-400.
2. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975; 83: 456-63.
3. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29 (Pt 1): 1253-60.
4. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002; 17: 289-96.
5. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al, REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
6. Matheson AJ, Spencer CM. Ropinirole. A review of its use in the management of Parkinson's disease. Drugs 2000; 60: 115-37.
7. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49 (Suppl 1): S58-62.
8. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804.
9. 2 receptors of rat cerebral cortex. Gen Pharmacol 1986; 17: 57-62.
10. 2 agonist (SK&F101468-A). Pharmacol Biochem Behav 1991; 38: 147-54.
11. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm 1999; 56: 217-24.
12. SmithKline Beecham Pharmaceuticals. Ropinirole: summary of product characteristics. Essex, UK: SmithKline Beecham Pharmaceuticals; 1999.
13. Boothman BR, Spokes EG. Pharmacokinetic data for ropinirole. Lancet 1990; 29: 814.
14. Taylor A, Beerahee A, Citerone D, Davy M, Fitzpatrick K, et al. The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Br J Clin Pharmacol 1999; 47: 219-22.
15. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13: 234-41.
16. 2-like receptor agonist. Eur J Pharmacol 1994; 14: 17-26.
17. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393-9.
18. 2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998; 21: 101-7.
19. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of 3-year study. The 053 Study Group. Mov Disord 1998; 13: 46-51.
20. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3 year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999; 53: 364-70.
21. Clarke CE, Deane KHO. Ropirinol versus bromocriptina para las complicaciones inducidas por levodopa en la enfermedad de Parkinson. In: Biblioteca Cochrane Plus; 2006. No. 1. Oxford: Update Software.
22. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients whit early Parkinson's disease who were treated with ropinirole or levodopa. The 056 Study Group. N Engl J Med 2000; 342: 1484-91.
23. Rascol O, Korczyn AD, De Deyn PP. Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson's disease (PD) initially receiving ropinirole or L-dopa [abstract]. Mov Disord 2005; 20 (Suppl 10): 21.
24. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, 043 Study Group. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002; 109: 489-502.
25. Brunt ER, Korczyn AD, Lieberman A. The long term efficacy of ropinirole as an adjunct to L-dopa. Neurology 1999; 51: 408-9.
26. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51: 1057-62.
27. Clarke CE, Deane KHO. Ropinirol para las complicaciones motoras inducidas por levodopa en la enfermedad de Parkinson. In: Biblioteca Cochrane Plus; 2006. No. 1. Oxford Update Software.
28. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa induced fluctuations in patients whit Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-45.
29. Weiner WJ, Minagar A, Shulman LM. Ropinirole after pramipexole failure in advanced Parkinson's disease. Ann Neurol 1998; 44: 502.
30. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003; 20: 847-55.
31. Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. Dual dopamine agonist treatment in Parkinson's disease. J Neurol 2003; 250: 822-6.
32. Stocchi F, Berardelli A, Vacca L, Thomas A, De Pandis MF, Modugno N, et al. Combination of two different dopamine agonist in the management of Parkinson's disease. Neurol Sci 2002; Suppl 2: 15-6.
33. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002; 360: 1767-9.
34. Parkinson Study Group. Dopamine transporter brain imaging to asses the effects of pramipexole versus levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.
35. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of levodopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001; 56: 1559-64.
36. Rakshi JS, Pavese N, Uema T, Ito K, Morrish PK, Bailey DL, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002; 109: 1433-43.
37. Jost WH. Ropinirol: situación actual de los estudios. J. Neurol Supl Ed Esp 2005; S6: 16-21.
38. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003; 26: 146-50.
39. Broocks DJ. Dopamine agonist: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 68: 685-9.
40. Lees AJ. Ropinirole: a viewpoint. CNS Drugs 1997; 8: 343.
41. Roth J, Ulmanova O, Ruzicka E. Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment. Cas Lek Cesk 2005; 144: 123-6.
42. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-61.
43. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-83.
44. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26: 439-44.
45. Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharm 1998; 21: 169-75.
46. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonist in Parkinson's disease. Mov Disord 2003; 18: 659-67.
47. Olanow W, Schapira A, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord 2000; 15: 212-5.
48. Kunkler RB, Osborn DE, Abbott RJ. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Br J Urol 1998; 82: 147.
49. Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004; 19: 1522-3.
50. 2B receptor activation plays crucial role. Mov Disord 2004; 19: 1523-4.
51. Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopamine agonists and fibrotic valvular heart disease: further considerations. Mov Disord 2004; 19: 1524-5.
52. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004; 19: 1370-4.